Bringing Drugs to Clinics Faster with NVIDIA Computing
About This Webcast
In the last decade, there have been dramatic advances in the field of computer-aided drug discovery. Researchers can now better understand causal biology, more effectively search through chemical space, and design de novo molecules that aim to treat disease. In this presentation, we will provide an inside look into: How Schrodinger uses NVIDIA-powered solutions to drive their in-silico drug discovery platform and recent NVIDIA optimizations to the Schrodinger suite. How organizations can easily implement the Schrodinger platform at scale, on premises, or in the cloud.
Speakers
Sathesh Bhat
Ph.D., Executive Director in the Drug Discovery Group , Schrödinger
Sathesh Bhat joined Schrödinger in 2011. He is responsible for overseeing computational chemistry efforts on internal and partnered drug discovery programs at Schrödinger. Previously, Sathesh worked at both Merck and Eli Lilly leading computational efforts in several drug discovery programs. He obtained his Ph.D. from McGill University, which involved developing structure-based methods to predict binding free energies. Sathesh has co-authored multiple patents and publications and continues to publish on a wide variety of topics in computational chemistry.
Rory Kelleher
Global Director and Head of Business Development for Healthcare , NVIDIA
Kelleher joined NVIDIA in 2016 leading the Healthcare business for the Eastern US, helping organizations tap into the NVIDIA ecosystem and expertise to adopt, develop, and deploy intelligent and accelerated applications. Prior to NVIDIA, Kelleher spent a decade in business development and sales leadership positions at technology firms Cisco Systems and EMC Corp. ated applications.